Cancer stem cells and the impact of Chinese herbs, isolates and other complementary medical botanicals: A review

Journal of Chinese Integrative Medicine

Volumn 10, Issue 5, 2012, Pages 493-503

  Weber, Daniel A ^a,b,c   Wheat, Janelle M ^a,d   Currie, Geoffrey M ^a,d  

^a CHARLES STURT UNIVERSITY   (Australia)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c World Federation of Chinese Medical Societies   (China)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

Cell hypoxia; Chinese herbal; DNA methylation; Drugs; Neoplastic stem cells; Review; Telomerase; Telomere

Indexed keywords

BERBAMINE; CURCUMIN; DNA; FLAVONE DERIVATIVE; FLUOROURACIL; GINSENOSIDE RG 3; OXALIPLATIN; PARTHENOLIDE; PLANT MEDICINAL PRODUCT;

CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CHINESE HERB; CHINESE MEDICINE; DNA METHYLATION; EPIGENETICS; HERBAL MEDICINE; HUMAN; HYPOXIA; INFLAMMATION; METABOLISM; METASTASIS; NONHUMAN; REVIEW; STEM CELL NICHE; SYSTEMATIC REVIEW; TELOMERE SHORTENING; TUMOR MICROENVIRONMENT;

ANIMALS; DRUGS, CHINESE HERBAL; HUMANS; NEOPLASTIC STEM CELLS; PHYTOTHERAPY;

EID: 84861637418     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20120503     Document Type: Review

References (94)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7): 3983-3988.
2. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5): 555-567.
3. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011; 29(1): 32-45.
4. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005; 97(20): 1498-1506.
5. Quante M, Wang TC. Inflammation and stem cells in gastrointestinal carcinogenesis. Physiology (Bethesda). 2008; 23: 350-359.
6. Saebøe-Larssen S, Fossberg E, Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol Biol. 2006; 7: 26.
7. Scadden DT. The stem-cell niche as an entity of action. Nature. 2006; 441(7097): 1075-1079.
8. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science. 2000; 287(5457): 1427-1430.
9. Li F, Tiede B, Massague J, Kang Y. Beyond tumori- genesis: cancer stem cells in metastasis. Cell Res. 2007; 17(1): 3-14.
10. Xin ZT, Beauchamp AD, Calado RT, Bradford JW, Regal JA, Shenoy A, Liang Y, Lansdorp PM, Young NS, Ly H. Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood. 2007; 109(2): 524-532.
11. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19): 7011-7021.
12. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000; 183(2): 145-154.
13. Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci. 2009; 100(7): 1166-1172.
14. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001; 19(3): 193-204.
15. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006; 355(12): 1253-1261.
16. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112(13): 4793-4807.
17. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007; 58: 267-284.
18. Clarke R. Regulation of human breast cancer stem-like cells. In: European School of Molecular Medicine. Abstract book of the International Workshop on Cancer Stem Cells. 2nd ed. Milan: IFOM-IEO Campus. 2007: 19.
19. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006; 66(19): 9339-9344.
20. Pollina EA, Brunet A. Epigenetic regulation of aging stem cells. Oncogene. 2011; 30(28): 3105-3126.
21. Boyle M, Wong C, Rocha M, Jones DL. Decline in self-renewal factors contributes to aging of the stem cell niche in the Drosophila testis. Cell Stem Cell. 2007; 1 (4): 470-478.
22. Jones DL. Aging and the germ line: where mortality and immortality meet. Stem Cell Rev. 2007; 3(3): 192-200.
23. Biteau B, Hochmuth CE, Jasper H. JNK activity in somatic stem cells causes loss of tissue homeostasis in the aging Drosophila gut. Cell Stem Cell. 2008; 3(4): 442-455.
24. Scaffidi P, Misteli T. Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells. Cold Spring Harb Symp Quant Biol. 2010; 75: 251-258.
25. Borovski T, De Sousa E, Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011; 71(3): 634-639.
26. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004; 432(7015): 324-331.
27. Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM. Lack of telomerase activity in human mesenchymal stem cells. Leukemia. 2003; 17 (6): 1146-1149.
28. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer. 2007; 96(7): 1020-1024.
29. Armanios M, Greider CW. Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol. 2005; 70: 205-208.
30. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266(5193): 2011-2015.
31. Harley CB. Telomerase therapeutics for degenerative diseases. Curr Mol Med. 2005; 5(2): 205-211.
32. Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. Eur J Cancer. 2006; 42(9): 1197-1203.
33. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015): 396-401.
34. Balk will F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255): 539-545.
35. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989; 49 (16): 4373-4384.
36. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat. 2000; 3(1): 39-47.
37. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824): 50-56.
38. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer. 2005; 41(18): 2792-2805.
39. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med (Berl). 2011; 89(3): 213-220.
40. Zhang M, Li X, Lewis MT, Chang JC, Rosen JM. Therapeutic resistance of breast cancer tumor-initiating cells. In: European School of Molecular Medicine. Abstract book of the International Workshop on Cancer Stem Cells. 2nd ed. Milan: IFOM-IEO Campus. 2007: 20.
41. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324 (5930): 1029-1033.
42. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol. 2000; 15(3): 835-842.
43. Kim KM, Shibata D. Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene. 2002; 21(35): 5441-5449.
44. Smith GH, Boulanger CA. Mammary stem cell repertoire: new insights in aging epithelial populations. Mech Ageing Dev. 2002; 123(11): 1505-1519.
45. Kim Y, Lin Q, Zelterman D, Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell sternness and tumorigenicity. Cancer Res. 2009; 69(24): 9271-9280.
46. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA. 1997; 94(6): 2545-2550.
47. de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessier E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011; 9(5): 476-485.
48. Lie DC, Colamarino SA, Song HJ, Désiré L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005; 437(7063): 1370-1375.
49. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11): 1148-1159.
50. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008; 27(50): 6522-6537.
51. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13(6): 1634-1637.
52. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ, Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010; 20(4): 440-446.
53. Gieni RS, Hendzel MJ. Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem Cell Biol. 2009; 87(5): 711-746.
54. Bock C, Paulsen M, Tierling S, Mikeska T, Lengauer T, Walter J. CpG island methylation in human lymphocytes is highly correlated with DNA sequence, repeats, and predicted DNA structure. PLoS Genet. 2006; 2(3): e26.
55. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, Chu FF, Pfeifer GP. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008; 68(24): 10280-10289.
56. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, Daley GQ, Feinberg AP. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009; 41(12): 1350-1353.
57. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005; 23: 879-894.
58. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004; 23(1-2): 11-27.
59. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977; 197(4302): 461-463.
60. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11(5): 1921-1929.
61. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279 (5349): 349-352.
62. Zhang Y, Lin HS. Tumor stem cells may be the final target of traditional Chinese medicine in preventing cancer recurrence and metastasis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009; 29(5): 461-463.
63. An YH, Song D, Yang LJ, Mao HL, Zhang C. Influence of soybean flavones to proliferation of liver cancer SMMC7721 cell lines and its tumor stem cells. Henan Yi Xue Yan Jiu. 2010; 19(4): 385-388.
64. Wei Y, Cao X, Ou Y, Lu J, Xing C, Zheng R. Se02 induces apoptosis with down-regulation of Bcl-2 and up- regulation of p53 expression in both immortal human hepatic cell line and hepatoma cell line. Mutat Res. 2001; 490(2): 113-121.
65. Liao DQ, Zhang JP, Fu YG, Yang GJ. The influence of ginsenoside Rg3 on the proliferation of glioma cancer stem cells in rats. Henan Zhi Gong Yi Xue Yuan Xue Bao. 2011; 23(2): 131-134.
66. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, Wong RN. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol. 2006; 72(4): 437-445.
67. Koprowska K, Czyz M. Molecular mechanisms of parthenolide' s action: Old drug with a new face. Postepy Hig Med Dosw (Online). 2010; 64: 100-114. Polish.
68. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Lies veld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007; 110(13): 4427-4435.
69. Wei YL, Xu L, Liang Y, Xu XH, Zhao XY. Berbamine exhibits potent antitumor effects on imatinib- resistant CML cells in vitro and in vivo. Acta Pharmacol Sin. 2009; 30(4): 451-457.
70. Wong CW, Seow WK, O'Callaghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on infcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. Agents Actions. 1992; 36(1-2): 112-118.
71. Xie J, Ma T, Gu Y, Zhang X, Qiu X, Zhang L, Xu R, Yu Y. Berbamine derivatives: a novel class of compounds for anti-leukemia activity. Eur J Med Chem. 2009; 44(8): 3293-3298.
72. Xu R, Dong Q, Yu Y, Zhao X, Gan X, Wu D, Lu Q, Xu X, Yu XF. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res. 2006; 30(1): 17-23.
73. Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer. 2009; 8: 81.
74. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010; 122(3): 777-785.
75. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol. 2009; 2(4): 321-328.
76. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7): 730-737.
77. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18): 5821-5828.
78. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015): 396-401.
79. + cancer stem cells in human solid tumours. PLoS One. 2008; 3(10): e3469.
80. Dirks PB. Cancer stem cells and brain tumors. Nature. 2006; 444(7120): 687-688.
81. Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, Gao L, Wang JM, Bian XW. Isolation and characterization of cancer stem cells from a human glioblastoma cell lineU87. Cancer Lett. 2008; 265(1): 124-134.
82. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65 (23): 10946-10951.
83. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005; 11: 729-737.
84. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005; 121(6): 823-835.
85. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445(7123): 111-115.
86. Yeung TM, Gandhi SC, Bodmer WF. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci USA. 2011; 108(11): 4382-4387.
87. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003; 17 (24): 3029-3035.
88. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005; 7(1): 17-23.
89. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007; 23: 675-699.
90. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11(3): 259-273.
91. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst. 1971; 46(2): 411-422.
92. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV. Stochastic cancer progression driven by non- clonal chromosome aberrations. J Cell Physiol. 2006; 208(2): 461-472.
93. Bruce WR, van der Gaa H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963; 199: 79-80.
94. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003; 3 (12): 895-902.